Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Rhea-AI Summary
Dermata Therapeutics (NASDAQ: DRMA) announced the Australian Patent Office has accepted its patent application for the DMT410 program for treating hyperhidrosis. This would be Dermata's second patent for DMT410, which uses Spongilla technology to topically deliver botulinum toxin for excessive sweating treatment.
The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for axillary hyperhidrosis. The upcoming Phase 2a study will explore DMT410's combination of a single XYNGARI™ application followed by a topical application of DAXXIFY®.
Gerry Proehl, Dermata's Chairman, President, and CEO, stated the acceptance further validates DMT410's innovative approach. Beyond hyperhidrosis, the company believes DMT410 holds promise for treating various skin conditions, including acne, rosacea, melasma, acne scars, and other aesthetic concerns.
The patent, entitled "Compositions for the treatment of skin conditions," will be automatically issued three months after acceptance unless opposed by a third party. Dermata also has an issued patent in Japan covering their DMT410 program for hyperhidrosis treatment.
Positive
- Australian Patent Office accepted DRMA's patent application for DMT410
- Clinical Trial Collaboration Agreement with Revance Therapeutics
- Phase 2a study planned for axillary hyperhidrosis treatment
- Already has an issued patent in Japan for DMT410
- Technology potentially applicable to multiple skin conditions beyond hyperhidrosis
Negative
- Patent not yet fully issued - still subject to potential third-party opposition
- Clinical trials for DMT410 still in early phases (Phase 2a)
- No revenue or commercialization timeline mentioned
Insights
Dermata Therapeutics' patent acceptance in Australia represents a significant intellectual property milestone for its DMT410 hyperhidrosis treatment program. This development, combined with their existing Japanese patent and recent Revance collaboration, creates a potentially valuable inflection point for this $6.4 million market cap biotech.
The global hyperhidrosis treatment market, valued at approximately $1.6 billion and growing at 5.9% annually, represents a substantial opportunity. Current treatments are dominated by botulinum toxin injections, which are effective but invasive and painful. Dermata's innovation lies in its proprietary Spongilla technology (XYNGARI™), which creates microchannels in the skin allowing for topical delivery of botulinum toxin – potentially transforming the treatment paradigm from painful injections to a simple topical application.
The collaboration with Revance Therapeutics is particularly strategic. Revance's DAXXIFY® is a next-generation botulinum toxin with demonstrated longer duration than BOTOX®. By combining Dermata's delivery technology with Revance's neurotoxin, DMT410 could offer patients a needle-free alternative with extended efficacy. For Dermata, this partnership provides access to Revance's resources and expertise, potentially accelerating development while sharing costs.
From an investment perspective, several factors merit attention:
- Dermata's patent portfolio now spans multiple major markets, creating potential licensing opportunities beyond their direct commercialization efforts
- The upcoming Phase 2a study represents a near-term catalyst; positive data could dramatically revalue the company
- The technology platform has applications beyond hyperhidrosis, including aesthetic indications like acne and rosacea, multiplying the potential market opportunity
However, investors should recognize that Dermata, like most microcap biotechs, faces significant challenges. With cash reserves, the company will likely require additional financing before commercialization. Additionally, while the patent acceptance strengthens their position, the Phase 2a study results remain the critical value driver – clinical success is far from guaranteed at this stage of development.
This patent acceptance ultimately enhances Dermata's competitive positioning in the hyperhidrosis market while providing additional validation for their innovative drug delivery platform. The Revance collaboration adds credibility to their approach and could potentially accelerate their path to market.
- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -
- The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis -
SAN DIEGO, CA / ACCESS Newswire / February 25, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the Australian Patent Office has accepted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," (Australian Patent Application No. 2109284621) continues to strengthen Dermata's global intellectual property portfolio for DMT410 for the treatment of hyperhidrosis. The patent will be automatically issued three months after acceptance unless a third party files an opposition.
"We are thrilled to receive this acceptance as we believe it further validates DMT410's innovative approach to delivering botulinum toxin topically for the treatment of hyperhidrosis," said Gerry Proehl, Dermata's Chairman, President, and CEO. "We see significant opportunities for our DMT410 program, and we are eager to move forward with our planned Phase 2a study in collaboration with Revance Therapeutics, who also has DAXXIFY® approved in Australia. This Phase 2a study will explore DMT410, which combines a single application of XYNGARI™ followed by a topical application of DAXXIFY® for the treatment of axillary hyperhidrosis. Beyond hyperhidrosis, we believe DMT410 holds promise as a versatile treatment for a range of skin conditions, including acne, rosacea, melasma, acne scars, and other aesthetic concerns that are in need of more effective solutions," Mr. Proehl added.
About DMT410
DMT410 is the Company's combination treatment regimen that uses the unique mechanical features of the Company's XYNGARI™ product candidate to facilitate the intradermal delivery of botulinum toxin by topical application rather than through multiple injections with a needle. The treatment consists of an initial topical application of XYNGARI™ to the treatment area where the microscopic spicules penetrate the stratum corneum to create microchannels into the dermis allowing for the topical application and penetration of botulinum toxin. The Company has successfully completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis and for the treatment of multiple aesthetic skin conditions. Both studies showed promising efficacy results and appeared to be safe and well tolerated by patients. The Company is also planning to initiate a Phase 2a study of DMT410 (XYNGARI™ with DAXXIFY®) for the treatment of axillary hyperhidrosis.
About Dermata Therapeutics
Dermata Therapeutics is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. Dermata's lead product candidate, XYNGARI™ (formerly DMT310), is its first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. In addition to acne, XYNGARI™ has been studied for the treatment of psoriasis and rosacea. Dermata's second program, uses XYNGARI™ as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin diseases and conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: expectations with regard to the timing of meetings and/or responses from submissions with regulatory bodies, including the FDA; the uncertainties inherent in clinical trials; expectations with regard to any potential partnership opportunities for any of the Company's product candidates; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; the success, cost, and timing of its product candidate DMT410 development activities and ongoing and planned clinical trials; whether the results of any planned clinical trials of DMT410 will lead to future product development; whether pending patent applications will proceed to allowance without interruption, if at all; and whether pending, accepted, or issued patents will provide adequate protection for the Company's product candidates, if approved. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
FAQ
What is Dermata's DMT410 technology for hyperhidrosis treatment?
What milestone did DRMA achieve with the Australian Patent Office?
What clinical trials is Dermata (DRMA) planning for DMT410?
What other skin conditions could Dermata's DMT410 potentially treat beyond hyperhidrosis?
How does Dermata's patent acceptance in Australia strengthen its global intellectual property portfolio?
